Garenoxacin

Drugbox
IUPAC_name = 1-cyclopropyl-8-(difluoromethoxy)-7- [(1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl] -4-oxoquinoline-3-carboxylic acid

---

CAS_number = 91421-42-0
ATC_prefix = J01
ATC_suffix = MA19
PubChem = 124093
DrugBank =
C = 23 |H = 20 |F = 2 |N = 2 |O = 4
molecular_weight = 426.412 g/mol
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_category =
legal_status =
routes_of_administration = Oral

Garenoxacin (INN) is a quinolone antibiotic for the treatment of gram-positive and gram-negative bacterial infections.

It was discovered by Toyama Chemical Co., Ltd. of Tokyo, Japan, and is currently being marketed in Japan under the tradename Geninax. Schering-Plough holds worldwide rights for garenoxacin, except for Japan, South Korea, and China.

On February 13, 2006, Schering-Plough announced that the United States Food and Drug Administration has accepted the New Drug Application (NDA) for garenoxacin, and has been granted a 10-month review. [cite web |url=http://www.drugs.com/nda/garenoxacin_060213.html |title=Drugs.com, Schering-Plough Reports Garenoxacin NDA Accepted for FDA Review |accessdate=2008-03-25 |format= |work= ]

References